DURECT (DRRX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif., August 13, 2024 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announ ...